Research programme: mitochondrial disorders therapeutics - Mitopharm/NeuroVive

Drug Profile

Research programme: mitochondrial disorders therapeutics - Mitopharm/NeuroVive

Alternative Names: Ciclosporin derivatives - NeuroVive; mPT inhibitors; NICAM; NVP 015; NVP 016; NVP 017; Succinate Prodrugs - NeuroVive/Lund; Succinic acid derivatives - Mitopharm/NeuroVive

Latest Information Update: 09 May 2014

Price : $50

At a glance

  • Originator Mitopharm Limited; NeuroVive Pharmaceutical
  • Class Ciclosporins; Succinic acids
  • Mechanism of Action Cyclophilin D inhibitors; Mitochondrial permeability transition pore inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Mitochondrial disorders
  • Research Acute heart failure; Cancer; Obesity; Stroke

Most Recent Events

  • 08 Jan 2014 Preclinical trials in Mitochondrial disorders in Sweden (IV)
  • 15 Oct 2012 Three drug candidates identified that increase mitochondrial energy production
  • 15 Oct 2012 Selcia Limited is now called Mitopharm Limited
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top